Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery

Raffaella Di Luzio1
Rachele Dusi2
Arianna Mazzotti2,3
Maria Letizia Petroni2
Giulio Marchesini2
Giampolo Bianchi2

1Unit of Internal Medicine – AUSL Bologna, Bologna, Italy; 2Department of Medical and Surgical Sciences (DIMEC), “Alma Mater” University, Bologna, Italy; 3Diabetes Unit, AUSL Romagna, Ravenna, Italy

Purpose: Hyperglycemia in trauma patients may stem from metabolic response to stress, both in the presence and the absence of underlying diabetes. We aimed to test the association of stress hyperglycemia with risks of adverse events subjects undergoing orthopedic surgery.

Patients and Methods: In a prospective observational study, we enrolled 202 consecutive patients with hyperglycemia at hospital admission for trauma injuries requiring orthopedic surgery. Based on history, diabetes was present in 183, and 13 more were defined as unknown diabetes on the basis of HbA1c ≥48 mmol/mol. Stress hyperglycemia was defined in subjects with/without diabetes by a stress hyperglycemia ratio (SHR) >1.14, calculated as admission glucose/average glucose, estimated from glycosylated hemoglobin. Logistic regression analysis was used to calculate the risk of post-surgery adverse events associated with different states of hyperglycemia, after correction for demographic and clinical confounders.

Results: Stress hyperglycemia was diagnosed, either as superimposed to diabetes (54/196 cases, 27.6%) as well as in the 6 cases without diabetes. At least one complication was recorded in 68 cases (33.7%), the most common being systemic infection (22.8% of cases). In the total cohort, stress hyperglycemia, irrespective of the presence of diabetes, increased the risk of adverse events (any events, odds ratio [OR], 4.43; 95% confidence interval [CI], 2.11–9.30), cardiovascular events (OR, 7.09; 95% CI, 2.47–19.91), systemic infections (OR, 4.21; 95% CI, 1.97–9.03) and other adverse events (OR, 6.30; 95% CI, 1.41–28.03), after adjustment for confounders; hospital stay was much longer. The same was true when the analysis was limited to the diabetes cohort or by comparing pure stress hyperglycemia vs diabetes without stress hyperglycemia.

Conclusion: The study highlights the importance of stress hyperglycemia for adverse events in the setting of orthopedic surgery following trauma injuries. This condition requires stricter management, considering the much longer length of hospital stay and higher costs.

Keywords: adverse events, comorbidities, hospital stay, infections, trauma

Introduction

Hyperglycemia is common in daily practice with hospitalized individuals, present in nearly 25–35% of Italian patients at admission. The prevalence is dictated by the high prevalence of diabetes in the elderly (much more commonly admitted than young individuals) and by stress-induced hyperglycemia, i.e., the elevation in blood glucose levels during periods of illness, resulting in remarkable metabolic stress. Mild-to-moderate stress hyperglycemia is protective, providing fuel for the immune system and brain at a time of stress; however, persistent hyperglycemia and insulin...
resistance may be potentially deleterious in the long run, directly contributing to adverse outcomes via endothelial dysfunction, increased free radical production (oxidative stress), inflammatory responses, vascular and immune dysfunction. A relationship between admission plasma glucose concentration and in-hospital mortality has long been established. Hyperglycemia has been associated with increased risks of congestive heart failure and mortality, both during the acute phase and the long-term follow-up of myocardial infarction, of mortality for community-acquired bacteremia, of acute respiratory failure in subjects with chronic obstructive pulmonary disease, as well as of mortality, poor functional recovery and transformation into hemorrhagic stroke in subjects with ischemic vascular disease.

Acute hyperglycemia following traumatic injury has also received a lot of attention; traumatic injuries induce stress hormone secretion, largely mediated by glucagon, in turn promoting oxidative stress and insulin resistance, finally resulting in hyperglycemia. Admission blood glucose represents a clinically useful predictor of mortality and infectious outcome in traumatically injured patients, and achieving normoglycemia in the early post-traumatic period may reduce the risk.

The definition of stress hyperglycemia remains difficult at the time of the event. Without evidence of prior diabetes, hyperglycemia during acute events could also stem from undiagnosed diabetes, where the elevated blood glucose remains an independent risk factor for complication. A recent study defined relative hyperglycemia (stress hyperglycemia ratio [SHR], ie, admission glucose divided by the estimated average glucose derived from glycosylated hemoglobin) as a tool to detect stress hyperglycemia. As such, SHR controls for background blood glucose and was shown to be a better biomarker of critical illness than absolute hyperglycemia.

We tested the reason(s) for hyperglycemia in a consecutive series of subjects undergoing orthopedic surgery in order to determine the presence of stress hyperglycemia and its association with the final outcome. Data may be relevant for tailored intervention and proper management.

Materials and Methods

Patients

This was an observational, prospective cohort study carried out in two Orthopedics units of the University Hospital Sant’Orsola-Malpighi and Rizzoli Orthopedic Institute of Bologna (Italy). The study included consecutive patients aged ≥18 years, admitted with injuries requiring acute intervention and hyperglycemia at the time of admission. Patients with orthopedic injuries non-requiring operative intervention, under corticosteroid treatment or critical illnesses were excluded.

The demographic and clinical data at entry are reported in Table 1. The distinction between minor or major surgery was obtained by the use of current tables of anesthesia and resuscitation Units (Supplementary Material). Following the demonstration of hyperglycemia, all cases were insulin-treated until glucose normalization or discharge from hospital, when they were referred to specialized diabetes units. The whole study received approval by the ethical committees of the participating institutions and was conducted according to the Helsinki declaration. The patients signed an informed consent to participation and anonymous data collection.

Methods

Admission glucose was recorded as the first glucose measurement after admission; hyperglycemia was defined as: a) fasting glucose values ≥126 mg/dL (7 mmol/L) from venous blood or capillary blood; b) capillary or venous blood glucose levels ≥144 mg/dL (8 mmol/L) in patients tested in non-fasting conditions.

Patient information was recorded and included demographic characteristics, medical history, blood glucose on admission and during hospital stay, HbA1c, concurrent medical diagnoses, diet and/or drug treatment for glucose control, length of stay, and hospital outcome. From patient history, we calculated the age-adjusted Charlson Comorbidity Index. During the hospital stay, insulin treatment was immediately instituted and daily blood glucose was monitored with four bed-side capillary glucose measurements (three pre-meal blood glucose measurements and 1–2 hours after the evening meal) in pre- or post-surgical days or more frequently during the day of surgery.

Total hospital stay, needs for admission to intensive care unit (ICU) and re-intervention were recorded, as well as adverse events, with special consideration for local and systemic infections and cardiovascular (CV) events. Perioperative infectious complications were categorized as pneumonia, urinary tract infections, and surgical site infections. Surgical-site infection was defined as any case that required reoperation for an infection at the site of the index operation and was confirmed by the presence of either positive intraoperative cultures, pathology specimens with microbiologic pathogens, or visible gross purulence at the operative site.
Table 1 Baseline Demographic and Clinical Data from Patients of the Total Cohort. The Age-Adjusted Charlson Comorbidity Index Was Calculated on the Basis of Medical History

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>All Patients (n=202)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>74.4 ± 12.4</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>76.4 ± 15.2</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>165.1 ± 9.8</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>27.9 ± 4.5</td>
</tr>
<tr>
<td>Glycosylated A1c hemoglobin (%)</td>
<td>7.08 ± 1.00</td>
</tr>
<tr>
<td>Blood glucose (mg/dL)</td>
<td>164.7 ± 59.8</td>
</tr>
<tr>
<td>Serum hemoglobin (g/dL)</td>
<td>12.6 ± 1.8</td>
</tr>
<tr>
<td>Serum potassium (mEq/L)</td>
<td>4.43 ± 0.54</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>1.00 ± 0.47</td>
</tr>
<tr>
<td>Age-adjusted Charlson Comorbidity Index</td>
<td>5.21 ± 2.12</td>
</tr>
</tbody>
</table>

Major surgery (%)* 85.6 (79.9–89.6)

Comorbidities (%)
- Arterial hypertension (%) 76.7 (70.2–81.8)
- Dyslipidemia (%) 37.1 (30.5–43.7)
- Coronary artery disease (%) 17.3 (12.5–22.9)
- Peripheral vascular disease (%) 15.8 (11.2–21.2)
- Chronic kidney disease (%) 10.9 (7.1–15.7)
- Retinopathy (%) 6.4 (3.6–10.4)
- Previous cancer (last 5 years) (%) 12.9 (8.7–17.9)
- Liver disease (%) 9.4 (5.9–13.9)

Previously diagnosed diabetes (N=183) (%) 90.6 (85.5–93.7)

Newly-detected diabetes (N=13) (%) 6.4 (2.8–13.2)

Diabetes treatment
- Diet only (N=18) (%) 9.8 (6.1–14.6)
- Metformin (N=63) (%) 34.4 (27.7–41.3)
- Any additional non-insulin drug (N=55) (%) 29.9 (23.5–36.6)
- Insulin + any non-insulin treatment (N=21) (%) 11.4 (7.4–16.5)
- Insulin alone (N=26) (%) 14.1 (9.8–19.6)

Relative hyperglycemia (SHR) 1.06 ± 0.34

Stress hyperglycemia (SHR >1.14) (N=58) (%) 28.9 (22.8–35.2)

Notes: Data are presented as means ± standard deviation. *Percent (95% confidence interval). **Estimated glomerular filtration rate <60mL/min/1.73m² (with/without albuminuria). °Percent within diabetes cohort (95% confidence interval).

Laboratory Tests
HbA1c is measured in the whole area of Bologna by a single laboratory, certified according to the initial DCCT rules and later as from the National Glycohemoglobin Standardization Program (NGSP). HbA1c was used to detect an unknown diabetic state (HbA1c ≥48 mmol/mol), as well as to estimate the average blood glucose concentration before admission using the equation: estimated average glucose (mg/dL) = (28.7*HbA1c [%]) – 46.7.

Relative hyperglycemia was defined by SHR, calculated as admission glucose divided by estimated average glucose. Values of SHR >1.14 were considered as indicative of stress-induced hyperglycemia, both in the presence and the absence of previously known diabetes. Using diabetes history, HbA1c and SHR as indicators, we grouped patients into three categories (Figure 1): a) diabetes/no stress hyperglycemia (SHR ≤1.1.14); b) diabetes/stress hyperglycemia (SHR >1.14); c) no diabetes/stress hyperglycemia (SHR >1.14).

We also categorized patients with stress hyperglycemia into quartiles of SHR in order to test the possible incremental role of stress hyperglycemia on the increased risk of complications.

Statistical Analysis
Statistical analysis was performed using StatView 5.0™ (SAS Institute Inc., Cary, NC) and SPSS for Windows v.21 (SPSS Inc., Chicago, IL, USA). Continuous variables were reported using mean and standard deviation (SD) or median and interquartile range (IQR), as appropriate. Absolute prevalence and percentage were used for categorical variables (dichotomous variables). Differences between continuous variables for the different cohorts were tested for significance using the Mann–Whitney U-test. Prevalence in different groups/subgroups was compared with Chi-squared test or with Fisher’s exact test when appropriate.

A logistic regression analysis was performed to ascertain the association of stress hyperglycemia with the different outcome variables, after adjusting for age, sex, body weight (BMI), comorbidities (age-adjusted Charlson’s index) and type of surgery. The relative risk of outcome variables was calculated as odds ratios (OR) and 95% confidence interval (CI). P values <0.05 were considered statistically significant.

Results
Admission Values
Two hundred and two patients satisfied the inclusion criteria and were considered in the analysis. Their baseline demographic data are reported in Table 1. The average body mass index (BMI) was 28.0 kg/m², in a wide range
One hundred and seventy-eight patients had a history of type 2 diabetes, 5 had Type 1 diabetes, and 19 showed hyperglycemia at hospital admission in the absence of a previous history of diabetes. In 13 cases, Hb A1c $\geq 48$ mmol/mol revealed a previously unreported diabetes. Most patients with diabetes were being treated with oral glucose-lowering agents alone, 23% with insulin (alone or in combination with oral agents), and the remaining 18% with the sole diet. In most cases (n = 173, 85.6%), surgical treatment fell within the criteria of major surgery. The average time from admission to surgery was 2.3 days (2.45 days in patients undergoing major surgery, 1.89 days for minor surgery), while 8.7 days was the average time from surgery to hospital discharge (9.58 days for major surgery; 4.58 days for minor surgery).

Several associated diseases were also recorded, as were diabetes-related comorbidities (16.3% of total cases). The age-adjusted Charlson comorbidity index was on average $5.2 \pm 2.1$, median 5.0 points; the score was neither different between genders nor between subjects in the three different cohorts.

**Glucose Values and Categories of Hyperglycemia**

The number of cases fitting the different classes of hyperglycemia are reported in Figure 1.

In 53/196 cases with diabetes (26.5%), hyperglycemia was exaggerated in comparison to the average blood glucose estimated from glycosylated hemoglobin (SHR $>1.14$) and the patients were considered to have stress hyperglycemia superimposed to diabetes. SHR was $\geq 1.14$ also in the remaining 6 cases, considered to represent pure stress hyperglycemia.

In comparison to subjects with diabetes and no stress hyperglycemia (reference) (Table 2), the presence of stress hyperglycemia superimposed to diabetes was characterized...
Table 2 Principal Characteristics and Adverse Events or Complications in Relation to the Presence of Diabetes and Stress Hyperglycemia

<table>
<thead>
<tr>
<th>Variable</th>
<th>Diabetes, No SH (N=143)</th>
<th>Diabetes, SH+ (N=53)</th>
<th>No Diabetes, SH+ (N=6)</th>
<th>P value^* DM (No SH vs SH+)</th>
<th>P value^* SH+ vs No SH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission glucose (mg/dL)</td>
<td>140.6 ± 34.5</td>
<td>230.1 ± 68.0</td>
<td>159.8 ± 7.8</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>7.11 ± 1.01</td>
<td>7.09 ± 0.97</td>
<td>6.10 ± 0.38^</td>
<td>0.887</td>
<td>0.425</td>
</tr>
<tr>
<td>Relative hyperglycemia</td>
<td>0.90 ± 0.17</td>
<td>1.47 ± 0.37</td>
<td>1.26 ± 0.13</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>73.5 ± 12.7</td>
<td>76.0 ± 11.6</td>
<td>83.3 ± 7.7</td>
<td>0.136</td>
<td>0.085</td>
</tr>
<tr>
<td>Charlson Index</td>
<td>5.08 ± 2.17</td>
<td>5.55 ± 2.01</td>
<td>5.50 ± 1.76</td>
<td>0.171</td>
<td>0.156</td>
</tr>
<tr>
<td>Type of surgery (Major)</td>
<td>120 (83.9, 76.8–88.7)</td>
<td>47 (88.7, 76.3–94.1)</td>
<td>6 (100.0, 51.7–100.0)</td>
<td>0.500</td>
<td>0.378</td>
</tr>
<tr>
<td>Cases with events</td>
<td>33 (23.1, 16.6–30.3)</td>
<td>29 (54.7, 40.6–66.5)</td>
<td>5 (83.3, 36.6–94.0)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardiovascular events</td>
<td>6 (4.2, 1.7–8.4)</td>
<td>10 (18.9, 9.9–30.3)</td>
<td>4 (66.7, 24.1–86.1)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AMI/angina</td>
<td>2 (1.4, 0.1–4.4)</td>
<td>2 (3.8, 0.7–11.4)</td>
<td>1 (16.7, 9.0–48.3)</td>
<td>0.296</td>
<td>0.150</td>
</tr>
<tr>
<td>Stroke/TIA</td>
<td>0 (0.0–0.0)</td>
<td>1 (1.9, 0.1–8.4)</td>
<td>0 (0.0–27.3)</td>
<td>0.270</td>
<td>0.292</td>
</tr>
<tr>
<td>Heart failure</td>
<td>1 (0.7, 0.0–3.3)</td>
<td>5 (9.4, 3.5–19.1)</td>
<td>1 (16.7, 9.0–48.3)</td>
<td>0.065</td>
<td>0.003</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>4 (2.5, 0.4–7.7)</td>
<td>5 (9.4, 3.5–19.1)</td>
<td>2 (33.3, 6.0–63.5)</td>
<td>0.062</td>
<td>0.016</td>
</tr>
<tr>
<td>Local infections</td>
<td>3 (2.1, 0.5–5.5)</td>
<td>2 (3.8, 0.7–11.4)</td>
<td>0 (0.0–27.3)</td>
<td>0.613</td>
<td>0.639</td>
</tr>
<tr>
<td>Systemic infections</td>
<td>21 (14.7, 9.5–21.0)</td>
<td>22 (41.5, 28.4–54.0)</td>
<td>3 (50.0, 13.9–75.9)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other complications</td>
<td>3 (2.1, 0.5–5.5)</td>
<td>6 (11.3, 4.7–21.4)</td>
<td>1 (16.7, 9.0–48.3)</td>
<td>0.013</td>
<td>0.007</td>
</tr>
<tr>
<td>ICU admission</td>
<td>6 (4.2, 1.7–8.4)</td>
<td>4 (7.5, 2.4–16.6)</td>
<td>1 (16.7, 9.0–48.3)</td>
<td>0.464</td>
<td>0.304</td>
</tr>
<tr>
<td>Reintervention</td>
<td>0 (0.0–0.0)</td>
<td>3 (5.7, 1.5–15.1)</td>
<td>1 (16.7, 9.0–48.3)</td>
<td>0.177</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Notes: Data are presented as means ± SD or as number of cases (%). 95% confidence interval). ^Student t-test, ^Fisher exact test, Student t-test, Chi^2 test or Fisher exact test, as appropriate.

Abbreviations: AMI, acute myocardial infarction; ICU, intensive care unit; TIA, transient ischemic attack; SH, stress hyperglycemia.

The rates of complicating events were different in relation to categories of hyperglycemia. In comparison to subjects with diabetes and no stress hyperglycemia (reference) (Table 2), the presence of stress hyperglycemia superimposed to diabetes was characterized by higher rates of cardiovascular events and systemic infections. These complications were very common also in the small group of cases with stress hyperglycemia in the absence of diabetes. When all cases with stress hyperglycemia were grouped, the resulting cohort was also characterized by significantly higher rates of arrhythmias and reintervention (Table 2).

Outcomes

The association of hyperglycemia category with outcomes is reported in Table 3, where diabetes without stress hyperglycemia was considered as the reference category. In the whole population with diabetes, stress hyperglycemia significantly increased the risk of adverse events, excluding local infections. In subjects with stress hyperglycemia without diabetes, only the significant association with cardiovascular events was maintained, with the limits of a limited number of cases. When all cases with stress hyperglycemia were merged, stress hyperglycemia was associated with four-time increased risk of adverse events, over ten-time increased risk of cardiovascular events.

by higher blood glucose levels at admission, but no systematic differences in HbA1c, age and comorbidities.

In-Hospital Events

During hospitalization, patients were monitored for the development of post-operative complications, including the possible need for a re-intervention, unplanned admissions to ICU and death. At least one complication was recorded in 68 cases (33.7%)(32.2% following major surgery, 1.5% after minor surgery). The most common complication was systemic infection (22.8% of cases), with/without local infection at the surgical site, which occurred alone in 7.3% of cases. As to cardiovascular complications, 2.5% of patients developed a coronary event, 3.5% acute heart failure and 5% atrial fibrillation. Only one patient experienced a transient cerebrovascular accident (0.5%), while no patients developed acute renal failure. Another 5% of cases were complicated by a miscellanea of obstructive airway episodes, acute cholecystitis, respiratory failure, epileptic crises, pericarditis, partial bowel obstruction and acute liver failure; 2.5% of cases experienced at least one hypoglycemic episode. Unplanned admission to ICU was required in 5.4% of patients, while 4 (2%) required re-intervention. Only one patient (0.5%) died during hospitalization; 43.6% received at least one unit of packed red blood cells.
Our results confirm the detrimental effect of this definition of stress hyperglycemia, to be confidently used in future prospective studies. A rapid assessment of stress hyperglycemia might be particularly useful in conditions where surgery should be carried out without proper preparation.

Table 3 Association of Hyperglycemia Categories with Adverse Events in Subjects with/Without a History of Diabetes

<table>
<thead>
<tr>
<th>Hyperglycemia Categories</th>
<th>All Adverse Events (N=68)</th>
<th>Odds Ratio (95% Confidence Intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CV Events* (N=19)</td>
<td>Systemic Infections (N=46)</td>
</tr>
<tr>
<td>1. Diabetes, no SH (reference) (n = 54)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2. Diabetes, SH+ (n = 42)</td>
<td>4.03 (1.95–8.32)</td>
<td>5.51 (1.83–18.80)</td>
</tr>
<tr>
<td>3. No diabetes, SH+ (n = 6)</td>
<td>13.08 (1.25–100.3)</td>
<td>44.52 (4.70–422.1)</td>
</tr>
<tr>
<td>4. Stress hyperglycemia (all cases: 2+3)(n = 48)</td>
<td>4.43 (2.11–9.30)</td>
<td>7.09 (2.47–19.91)</td>
</tr>
</tbody>
</table>

Notes: All data are adjusted for age, sex, body mass index, Charlson’s index and type of surgery. Statistically significant results are presented in bold characters.

Abbreviations: SH, Stress hyperglycemia; CV, cardiovascular; ICU, intensive care unit; na, data not calculated because of lack of events.

Discussion

The study highlights the importance of stress hyperglycemia in the development of complications in the specific setting of subjects undergoing orthopedic surgery following traumatic injuries. Irrespective of the presence of overt or newly-discovered diabetes, the risk of adverse events increases several times whenever blood glucose exceeds the values corresponding to the measured glycosylated hemoglobin. This condition also requires a different management, considering the longer length of hospital stay and is expected to carry much higher costs.

Our analysis is based on the assessment of SHR, a tool to detect stress hyperglycemia suggested and validated in a large clinical setting by Roberts et al. This tool appears to be particularly useful since it provides an assessment of stress-induced hyperglycemia also in the presence of underlying diabetes, which might blur the response to stress. In the original proposal, SHR was demonstrated to be independently associated with critical illness to a much larger extent than absolute hyperglycemia, largely driven by diabetes and glucose-lowering treatment. The SHR cut-off to define stress hyperglycemia has never been definitely validated. We choose a value of 1.14, i.e., the average value previously shown to be associated with an increased rate of adverse events. The SHR value also demonstrates a linear effect on the occurrence of adverse events, along the whole range of SHR values. In a post hoc analysis of our population, where subjects with SHR > 1.14 were divided into quartiles, the odds ratios of adverse events progressively increased from 3.82 (2nd quartile) to 4.16 (3rd quartile) and finally to 6.95 (4th quartile). Similar results were also observed in the original study. Our results confirm the detrimental effect of this definition of stress hyperglycemia, to be confidently used in future prospective studies. A rapid assessment of stress hyperglycemia might be particularly useful in conditions where surgery should be carried out without
any delay, as in traumatic injuries, and particularly in older patients, where diabetes may frequently occur.

Dungan et al suggested that stress hyperglycemia might be a physiological response to stress-induced insulin resistance, via a possible modulation of glucose transporters, independently of diabetes. However, hyperglycemia per se amplifies the inflammatory response, possibly increasing the risk of adverse events. In our setting the risks for adverse events in subjects with stress hyperglycemia in the absence of diabetes are generally elevated compared to diabetes without stress hyperglycemia, although difficult to define due to the limited sample size. In general, the higher risk of adverse events is confirmed to involve different organs and systems, suggesting that a general abnormal response to stress might be the common driver.

If stress hyperglycemia drives complications, the type and target organ is likely to vary according to a specific setting. In surgical patients, the risk for surgical site infection is particularly critical and adds to the cardiovascular risks previously demonstrated in other settings. Several large studies have consistently associated the presence of diabetes with surgical site infections. In a large database on 13,272 patients who underwent primary joint arthroplasty between 2001 and 2011, Chrastil et al found was no increased risk of infection associated with elevated glycosylated hemoglobin, whereas preoperative hyperglycemia was associated with an increased incidence of perioperative joint infection again in keeping of a major risk of stress-induced hyperglycemia. In a review article and meta-analysis of surgical procedures, Martin et al found an increased risk for surgical site infection associated with diabetes (OR, 1.53; 95% CI, 1.11–2.12), and lower values for orthopedic surgery (arthroplasty, OR 1, 26), but they also concluded for a higher risk associated with glucose levels, after controlling for the presence of diabetes.

The risk of adverse events associated with high SHR was particularly elevated in subjects without diabetes, who did not receive any treatment for their hyperglycemia. This points to a possible modulatory effect of glucose-lowering treatment on hyperglycemia and opens the question of systematic assessment of blood glucose and immediate and effective treatment with insulin at admission, as suggested by guidelines, independently of the presence of diabetes. Surgical site infections, independently of the presence of diabetes, are universally recognized as quality-of-care indicators. In an updated review based on an old report from the National Institute for Health and Clinical Excellence, Bock et al concluded that data did not support routine preoperative testing for blood glucose or HbA1c in apparently healthy adult patients undergoing elective noncardiac surgery. However, also in their analysis orthopedic surgery was worth a screening. The old age of the majority of patients undergoing elective surgery and the multiple comorbidities associated with diabetes are the likely reason for the difference in comparison to other elective surgeries. In our setting insulin treatment was immediately instituted in the presence of hyperglycemia at admission according to predefined protocols, but adverse events were nonetheless very common and clustered in subjects with stress-induced hyperglycemia. Tailored glucose-controlling, insulin-administering programs are needed to keep infection and non-infection complications to a minimum. Only a few well-designed controlled studies are available in the orthopedic setting, and the implementation of effective procedures in frail hyperglycemic patients by dedicated teams requires special attention.

**Conclusion**

Stress-induced hyperglycemia remains difficult to define at time of the event. In the setting of orthopedic surgery, our study confirms that the calculation of the stress hyperglycemia ratio provides a measure with a definite clinical significance. Larger studies are needed to define the precise cut-off of the ratio, both in the presence and the absence of overt diabetes, associated with clinical events, considering the prognostic information it provides. It should also be relevant to define how much the persistence of stress hyperglycemia will impact on adverse events.

**Abbreviations**

AMI, acute myocardial infarction; BMI, body mass index; CV, cardiovascular; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin; ICU, intensive care unit; SH, stress hyperglycemia; SHR, stress hyperglycemia ratio; TIA, transient ischemic attack.

**Acknowledgments**

The authors are indebted to Prof. Massimo Laus (Head, Orthopedic Unit, Sant’Orsola-Malpighi Hospital) and to Prof. Riccardo Meliconi (Head, Medical Department, IRCCS Rizzoli Hospital) for support in the study. The participation of both teams (medical and nurse personnel) is also acknowledged.

**Disclosure**

Giulio Marchesini reports he is on the advisory board for Gilead, Astra-Zeneca, Sanofi and Eli Lilly, outside the
submitted work. The authors report no conflicts of interest in this work.

References


